Gaspar Requena Aspas

10PUBLICATIONS
143CO-AUTHORS
NanomedicineCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMedical infection agents (incl. prions)Gene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Oct 06, 2026
Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnosed acute myeloid leukemia: a real-world study from the PETHEMA registry.

|Sep 04, 2026
Comparison of venetoclax and azacitidine versus a cytarabine-based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real-world study of the DATAML-IPC-AURAML consortium.

|Sep 01, 2026
Relationship Between Salvage Strategy and Outcomes in Patients With CBF or NPM1-mutated AML and First Molecular Relapse.

|Aug 31, 2026
Real-World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: The PETHRATIFY Study.

|Jul 17, 2026
Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry.

|Jul 02, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Pageof 2

Frequent Collaborators

7 joint publications

Emmanuelle Tavernier-Tardy

4 joint publications

Pau Montesinos

4 joint publications

Juan Miguel Bergua-Burgues

3 joint publications

Christian Recher